Tweets
Pragmatism in Gout: How therapeutic choices can have multiple benefits
Drugs prescribed to calm flares or lower uric acid are designed with one primary goal in mind, yet many also produce meaningful effects beyond the joints. Some of those secondary effects are unwelcome; such https://t.co/QvXAwFM7LJ
Dr. John Cush @RheumNow ( View Tweet )
11 minutes 33 seconds ago
Retrospective study of 2187 RA pts initiating menopausal hormone Tx (MHT) vs 8,205 unexposed controls. VTE incidence higher among MHT users (6.49 vs 3.3/1000PY). MHT use was associated with a 92% signif increased risk of VTE in RA (adj HR: 1.92), mostly DVT risk (aHR: 2.26)
Dr. John Cush @RheumNow ( View Tweet )
32 minutes 39 seconds ago
Psoriasis = Myocardial Dysfunction (unrelated to Cardiometabolic Risk Factors) 1010 PsO pts vs controls w/o skin dz, assessed clinically & by ECHO. PSO pts (even w/ controlled dz) had signif more myocardial dysfunction (17% vs 6%). Higher BMI & DM independently assoc w/ https://t.co/MjcRmgyCWX
Dr. John Cush @RheumNow ( View Tweet )
8 hours 40 minutes ago
STOP-HZ trial - 30 #RA pts going on tofacitinib given Shingrix (RZV) on day 1 & wk 8 & started Tofa on d1 or wk8. @wk 12 VZV responses incr in both (2.66 & 2.91 fold incr). @wk 4, d1 Tofa had fewer ≥1.5-fold VZV vs wk8 (44.8% vs 80%); BUT can you wait 8wks to start JAKi? https://t.co/tH0zPgBbHQ
Dr. John Cush @RheumNow ( View Tweet )
22 hours 41 minutes ago
Calcium Pyrophosphate Deposition Dz new terminology from 2026 G-CAN consensus. Preferred:
- acute CPP crystal arthritis
- Chronic CPP crystal arthritis
- Chronic CPP crystal arthritis
- OA w/ CPP
- Chondrocalcinosis (xray)
* Pseudogout is obsolete
https://t.co/L95N2ObHr3 https://t.co/ST7RkJa8BR
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
An AI model trained from routine electronic health record data of 3.7 million individuals predicted cancer 1 year before clinical onset, no less promoted accuracy in detection, staging, treatment response, and prognosis
https://t.co/ORrpJ2vIcR https://t.co/ymJWRAYOSw
Links:
Eric Topol @EricTopol ( View Tweet )
1 day 5 hours ago
UTSW observational study of labs (n 14,199) changes w/ MTX use in 2,439 pts (13% RA, 11% PsO/PsA, 15% inflam arthritis) - found no difference in labs q3 vs q6 mos. No signif correlation betw monitoring intervals & changes in ALT, AST,WBC, HCT, MCV, PLT, FIB-4. Small https://t.co/gKwA7juexG
Dr. John Cush @RheumNow ( View Tweet )
1 day 5 hours ago
RHEUMS! FINAL GOUT SURVEY ON NEW THERAPIES>> Which biologic is FDA-approved for gout? Answer here>> https://t.co/MWSnCZEDdR
Dr. John Cush @RheumNow ( View Tweet )
1 day 5 hours ago
Fibrosis-4 (FIB-4) Index for Liver Fibrosis is calculated from age, AST, ALT, Plts. Study of 174 RA, PsA, PsO pts on MTX find 11% w/ fibrosis (by elastography). FIB-4 AUC for fibrosis =0.68 (weak). Fibrosis was signif assoc w/ FIB-4 >1.62, DM, obesity, advanced steatosis https://t.co/GYrhs2U1s3
Dr. John Cush @RheumNow ( View Tweet )
1 day 6 hours ago
The Hidden Cost of Gout
For many people, gout is viewed as an episodic disease: a painful flare, a short course of treatment, and then life returns to normal. However, as rheumatologists, we know that recurrent attacks can lead to joint damage and tophi if left untreated. https://t.co/BfZFBZ8YrU
Dr. John Cush @RheumNow ( View Tweet )
1 day 8 hours ago
Primary biliary cholangitis is a chronic cholestatic disease characterized by autoimmune-mediated destruction of bile ducts, leading to fibrosis, cirrhosis, & liver failure. Ursodeoxycholic acid is 1st line Rx. New Rx include elafibranor & seladelpar (activates peroxisome https://t.co/tKloXvJYek
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
UK primary care database (2000–21) gout study of new colchicine initiators (n 31,478) vs noninitiators (mean 60 yrs, BMI 30), follow-up of 4.5 yrs. Colchicine use had a signif. 12% lower risk of Joint Arthroplasty (HR 0.88); 23% lower TJA in knee/hip OA (HR 0.77) https://t.co/bT07lUYBB2
Dr. John Cush @RheumNow ( View Tweet )
2 days ago


